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Management of chronic 
kidney disease and its 
risk factors in eastern 
Nepal
In the past two decades, com-
munity screening programmes for 
chronic kidney disease have been 
progressively increasing in rural 
and urban areas of low-income and 
middle-income nations.1 However, 
screened individuals are seldom 
maintained on active follow-up 
even when they have been identiﬁ ed 
with risk factors. This problem 
particularly applies to patients living 
in rural areas where major barriers 
are low awareness about renal 
disease and its management, and, 
more importantly, poor transport 
infrastructure and precarious family 
financial conditions that prevent 
young adults from taking time off 
work to attend city hospitals. 
To overcome this problem, the 
Department of Medicine of the BP 
Koirala Institute of Health Sciences 
(BPKIHS) in Dharan, Nepal, in 
collaboration with the International 
Society of Nephrology and the 
Clinical Research Center for Rare 
Diseases of the Mario Negri Institute 
for Pharmacological Research in 
Bergamo, Italy, set up a screening 
and intervention programme in 
rural communities of eastern Nepal 
to improve management of chronic 
kidney disease and its major risk 
factors. BPKIHS created a network of 
small health-care units in communities 
that can refer to primary health 
centres or district hospitals. Meetings 
were held initially with local leaders 
(administrators, local political leaders, 
and school teachers) to explain the 
beneﬁ ts of a screening and intervention 
programme. After these individuals 
gave their approval and support, 
a series of community awareness 
activities were carried out with the help 
of local leaders, community volunteers, 
and medical students and doctors 
from BPKIHS. 
For screening, all people aged 
18 years or older were invited to one 
of the small health-care units in close 
proximity to their houses. On the 
day of screening, the research team 
collected, via a short questionnaire, 
the patients’ general information, 
demographic data, diet, smoking 
habit, alcohol consumption, and 
physical activity. The data recorded 
included family and personal medical 
history of kidney disease, high blood 
pressure, diabetes, cardiovascular 
disease, and any present drugs or 
treatments. Height, weight, and 
blood pressure were measured in 
accordance with standard guide-
lines. A clean midstream spot 
urine specimen (to assess protein 
concentration) and blood samples 
(to test for fasting blood glucose and 
serum creatinine concentrations) 
were collected. High blood pressure, 
fasting hyperglycaemia, proteinuria, 
or impaired renal function were 
conﬁ rmed 10 to 15 days after samples 
were collected, and veriﬁ ed by qualiﬁ ed 
doctors. Patients with hypertension, 
hyperglycaemia, proteinuria, or renal 
function impair ment were invited 
to enter the follow-up study via 
scheduled visits at the health-care 
unit of the village or nearby. They were 
prescribed cheap antihypertensive, 
antidiabetic, or renoprotective drugs 
as deemed appropriate. 
Of 20 811 individuals screened in the 
communities of eastern Nepal within 
this programme,2 4471 participants 
who had high blood pressure or 
fasting blood glucose, proteinuria, 
or impaired renal function were 
followed up annually for 3 years. Of 
4471 participants, 3419 (76%) were 
on active monitoring after the 3 year 
follow-up. In this cohort, 697 (53%)
of 1315 individuals with high baseline 
systolic blood pressure had values 
reduced to a healthy range, as did 
878 (63%) of 1349 individuals with 
high baseline diastolic blood pressure, 
and 354 (55%) of 643 individuals 
with baseline hyperglycaemia. 63% of 
participants with dipstick proteinuria 
equal to or more than 1+ at baseline 
progressively decreased to normal 
values during the 3 year follow-up 
(table). In 48% of participants with 
mild-to-severe renal insufficiency 
(estimated glomerular ﬁ ltration rate 
[eGFR] <60 mL/min per 1·73 m²) at 
baseline, renal function improved 
(table). No participants progressed to 
end-stage renal disease, which would 
require renal replacement therapy 
with dialysis. The prevalence of 
participants with a predicted 10 year 
cardiovascular risk of 10% or more 
was 28% at baseline and decreased to 
17% after 3 years (table).3 
These findings show that an 
affordable local organisation can 
deliver substantial population-
wide benefits to manage chronic 
kidney disease and its risk factors 
in the resource-poor setting of 
eastern Nepal. In the long term, the 
programme is expected to decrease the 
prevalence of end-stage renal disease 
and the need for renal replacement 
therapy and reduce cardiovascular 
morbidity and mortality. Although 
the general approach adopted in 
Nepal could be an example suitable 
for other resource-poor countries 
with an increasing burden of non-
communicable diseases, the methods 
should ultimately suit local needs and 
 Baseline Visit 1 Visit 2 Visit 3
Dipstick proteinuria (n=456)
<1+ 0 225 (49%) 270 (59%) 287 (63%)
≥1+ 456 (100%) 231 (51%) 186 (41%) 169 (37%)
eGFR (mL/min per 1·73m²; n=1081)
>60 0 487 (45%) 499 (46%) 520 (48%)
<60 1081 (100%) 594 (55%) 582 (54%) 561 (52%)
Predicted 10 year cardiovascular risk (n=3418)
No risk 1193 (35%) ·· ·· 1718 (50%)*
<10% 1283 (38%) ·· ·· 1116 (33%)*
10–20% 374 (11%) ·· ·· 344 (10%)
20–30% 340 (10%) ·· ·· 170 (5%)*
30–40% 95 (3%) ·· ·· 25 (1%)*
>40% 133 (4%) ·· ·· 45 (1%)*
Data are expressed as number of individuals (% of baseline). eGFR=estimated glomerular 
ﬁ ltration rate. *p<0·0001 vs baseline.
Table: Risk factor prevalence in patients in a chronic kidney disease 
management programme in eastern Nepal
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factors such as health awareness, and 
account for availability of human and 
material resources.4,5
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